Compliance Team
Angels Den

Dear User,

You may have heard about the new General Data Protection Regulation (“GDPR”), that comes into effect May 25, 2018.

We would like to ensure you that your personal data is safe with us. Please read the details regarding the processing of your personal data and if you agree with the processing as described below, please click the ‘I agree’ button.

Please be informed that you can withdraw this consent at any time.

1) What data are we talking about?

We are disclosing details regarding the processing of personal data that is collected within our calls and in connection with your use of Angels Den’s platform, Websites and other functionalities of Angels Den, including those saved in cookies files.

2) Who will be the controller of your data?

Angels Den Funding Limited (hereinafter referred to as AD) will be the controller of your data (Angels Den means all entities from the Angels Den capital group, which includes Angels Den Funding Limited with its registered office in London and all entities related to it and dependent on it) and only our Trusted Partners.

3) Why do we want to process your data?

We process this data for the purposes described in our Privacy Policy, including:
- compliance with any legal requirements and obligations,
- ensuring that content from our Website is presented in the most effective manner for you,
- marketing purposes,
- providing you with our services (including the completion and support of immediate activity required to provide you with information and deliver products and/or services that you request and to deliver any contracts entered into with you), or
- as otherwise explained in this privacy policy or by any communication by us.
Where you have explicitly consented to be contacted for such purposes, we use your personal data to provide information on our new and existing products and services.

4) To whom can we transfer data?

In accordance with applicable law, we may transfer your data to entities processing it at our request, e.g. marketing agencies, subcontractors of our services and entities authorized to obtain data under applicable law, e.g. courts or law enforcement agencies - of course only if they submit a request based on an applicable legal basis. Furthermore, we will transfer your data to Trusted Partners outside the European Union – to the USA – under the EU-U.S. Privacy Shield Framework.

5) What are your rights to your data?

You have the right to request access to, correct, delete your personal data. You can also withdraw consent to processing of personal data, raise objections and use other rights granted under GDPR (i.e. right to data portability).

6) Use of cookies

We use cookies to give you the best experience on our Website. This means that we have placed cookies on your device. If you continue without changing your cookie settings, we assume that you consent to our use of cookies on this device. You can change your cookie settings at any time but if you do, you may lose some functionality on our Website. More information can be found in our Privacy Policy.

In connection with the above, I agree to the processing of my personal data by Angels Den and its Trusted Partners. I confirm that I understand that my personal data is being collected as part of my phone calls, use of AD’s online platform, Websites, and other functionalities of AD, including the data saved in cookie files. I also consent to profiling in order to allow Angels Den and its Trusted Partners the provision of better services (including for analytical purposes). Your data will only be processed on a valid lawful basis in accordance with applicable data protection laws. The processing of your personal data for marketing purposes (including statistical analysis) by AD is based on the firm's legitimate interest. The processing for marketing purposes by our Trusted Partners is only possible if we receive your freely given consent. We will also process your personal data to fulfil our contractual obligations to you as contained in AD’s Terms and Conditions of the use of our Website and services. Therefore, this data will be processed on another lawful basis – ‘contract’. We will also process your data to comply with our legal obligations for our Service (such as anti money laundering and know your customer requirements), which is also a valid lawful basis in accordance with applicable data protection laws.

Expressing this consent is voluntary and you can withdraw at any time.

If you have any doubts or questions about the use of your personal data, please do not hesitate to contact me via email. I’m happy to assist.

Compliance Team
Angels Den
cl@angelsden.com

CROSSR

We make drug discovery R&D exponential with our no code analytics platform

£ 150,000
9 Days left

50% of minimum goal raised

Lead investor: SFC Capital

Minimum Target

£ 300,000

Minimum investment amount

£ 10,000

Maximum Target

£ 500,000

Maximum investment amount

£ 500,000

Investment Opportunity

Since the human genome project we have more data than ever to use to create precision medicines for human disease. However 90% of drug discovery scientists cannot generate insights from biomedical datasets due to inability to code. We want to fix this by building a no code analytics platform, to exponentially speed up the pace of R&D, and a decentralised knowledge graph to generate rich, high quality datasets. Our platform can save research organisations such as pharmaceutical and biotech companies 10,000s of hours of scientist and bioinformatician time and millions in costs. It also opens up opportunities to develop precision medicines faster.

LIVE PITCHING

Crossr at Angels Den's AI/ML Pitching Event

You have to log in or register to see this information.
THE IDEA
Products & Services

We provide a software product that allows you to identify novel targets, better understand diseases and deploy recommender systems.

The product has several features including:
- Connected database representing biomedical knowledge across several domains including diseases, genes and compounds
- Knowledge graph visualisation and exploration, study knowledge graph connections to understand disease mechanisms
- Enrichment analysis, understand which biological processes are most implicated in a set of genes
- Causal Reasoning, determine the genetic drivers of diseases by assessing cause and effect within regulatory networks
- ML Sandbox, Rapidly deploy recommender systems and algorithm

Problem Solved

Biomedical datasets are becoming increasingly complex over time. However, 90% of wet lab researchers, the key drivers advancing medicines to patients, don't know the required coding languages (R and Python) to make sense of this data. Instead they request insights from bioinformaticians, however due to global shortage of bioinformaticians and high workload and backlog, turn around time for this sort of analysis is typically 3 weeks. This time delay in time to insight impacts pharmaceuticals greatly, for the average company this leads to 30,000s hours of dead time and over £1M in avoidable costs.

Revenue Model

Our core revenue model is licensing access to our software platform and datasets in a subscription model. The customer will pay an upfront setup fee and then a monthly/ yearly subscription fee for access to the software and data hosting infrastructure, engineering support, dedicated account manager and adoption support access to in house data science support. This revenue source will allow near-medium term sustainability of the company.

Our secondary revenue sources include decentralising our graph and partnering on IP and assets generated through the portal. IP ownership and codevelopment will lead to large downstream rewards.

Exit Strategy
You have to log in or register to see this information.

The Idea

Products & Services

We provide a software product that allows you to identify novel targets, better understand diseases and deploy recommender systems.

The product has several features including:
- Connected database representing biomedical knowledge across several domains including diseases, genes and compounds
- Knowledge graph visualisation and exploration, study knowledge graph connections to understand disease mechanisms
- Enrichment analysis, understand which biological processes are most implicated in a set of genes
- Causal Reasoning, determine the genetic drivers of diseases by assessing cause and effect within regulatory networks
- ML Sandbox, Rapidly deploy recommender systems and algorithm

Problem Solved

Biomedical datasets are becoming increasingly complex over time. However, 90% of wet lab researchers, the key drivers advancing medicines to patients, don't know the required coding languages (R and Python) to make sense of this data. Instead they request insights from bioinformaticians, however due to global shortage of bioinformaticians and high workload and backlog, turn around time for this sort of analysis is typically 3 weeks. This time delay in time to insight impacts pharmaceuticals greatly, for the average company this leads to 30,000s hours of dead time and over £1M in avoidable costs.

Revenue Model

Our core revenue model is licensing access to our software platform and datasets in a subscription model. The customer will pay an upfront setup fee and then a monthly/ yearly subscription fee for access to the software and data hosting infrastructure, engineering support, dedicated account manager and adoption support access to in house data science support. This revenue source will allow near-medium term sustainability of the company.

Our secondary revenue sources include decentralising our graph and partnering on IP and assets generated through the portal. IP ownership and codevelopment will lead to large downstream rewards.

Exit Strategy
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.
You have to log in or register to see this information.

Location

LONDON

Gallery